Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.74 |
| ▸ | CYP2J2 | P51589 | 5/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107804 | 0.88 | EPHX2 (0.70) | EPHX2CYP2C9CYP2J2CYP2C19GRIN2B | |
| SCHEMBL13873468 | 0.86 | EPHX2 (0.62) | EPHX2CYP2C9CYP2J2CYP2C19GRIN2B | |
| SCHEMBL4109820 | 0.85 | EPHX2 (1.00) | EPHX2CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL4106308 | 0.83 | EPHX2 (0.79) | EPHX2CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL13873763 | 0.81 | EPHX2 (0.61) | EPHX2CYP2C9CYP2J2CYP2C19GRIN2B | |
| SCHEMBL13873768 | 0.79 | EPHX2 (0.67) | EPHX2CYP2C9CYP2J2CYP2C19GRIN2B | |
| SCHEMBL13873769 | 0.79 | EPHX2 (0.81) | EPHX2CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL4109744 | 0.79 | EPHX2 (0.89) | EPHX2CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL13873459 | 0.79 | EPHX2 (0.81) | EPHX2CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL13873413 | 0.79 | EPHX2 (0.81) | EPHX2CYP2C9CYP2J2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| EP-1996545-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | Boehringer Ingelheim International GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 477/4885CYP2J2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.